ACADIA Pharmaceuticals Inc Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Congrats on the progress. Maybe just following up a bit on the AdCom in June. Very helpful to hear about maybe the mechanics and maybe the typicality of it. I'm just curious, Steve, if you could provide some color on how important you think a vote of confidence is from the panel, especially in light of that unique situation that you've certainly endured and having the differences in the view on the initial package that led to the CRL. And maybe just related -- and also related to just some of the history of AdComs and recommendations and how that leads to approvals or not. And maybe just a subpart I'll throw on in as well, just respect to the potential scenarios of that outcome, maybe provide some color about how you're thinking about scenario planning based on the vote outcomes once you go from June until August.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Ahead of the AdCom convention for ADP other than not having statistical significance for a specific ADP subgroup and HARMONY or what the FDA has already expressed on study 019. What are some of the specific nitpicks or pieces for the pushback if any, that your external KOLs or consultants might have on the data package you've been putting together for the meeting?

Question: Esther Lannie Hong - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So just wanted to ask on trofinetide. If you could provide any details on the open-label extension studies that are going on. Maybe if you can speak about patients who have continued on treatment and what's been observed.